Literature DB >> 6825120

Clinical evaluation of long-term, continuous-infusion doxorubicin.

M B Garnick, G R Weiss, G D Steele, M Israel, D Schade, M J Sack, E Frei.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6825120

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  11 in total

1.  A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study.

Authors:  Mathilde Hunault-Berger; Thibaut Leguay; Xavier Thomas; Ollivier Legrand; Françoise Huguet; Caroline Bonmati; Martine Escoffre-Barbe; Laurence Legros; Pascal Turlure; Patrice Chevallier; Fabrice Larosa; Frederic Garban; Oumedaly Reman; Philippe Rousselot; Nathalie Dhédin; André Delannoy; Marina Lafage-Pochitaloff; Marie Christine Béné; Norbert Ifrah; Hervé Dombret
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

Review 2.  Continuous infusion of low-dose doxorubicin, epirubicin and mitoxantrone in cancer chemotherapy: a review.

Authors:  J Greidanus; P H Willemse; D R Uges; E T Oremus; Z J De Langen; E G De Vries
Journal:  Pharm Weekbl Sci       Date:  1988-12-09

Review 3.  Clinical pharmacokinetics of doxorubicin.

Authors:  P A Speth; Q G van Hoesel; C Haanen
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

Review 4.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

5.  Pharmacokinetics of doxorubicin in man: dose and schedule dependence.

Authors:  R Erttmann; N Erb; A Steinhoff; G Landbeck
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

6.  Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion.

Authors:  C Muller; E Chatelut; V Gualano; M De Forni; F Huguet; M Attal; P Canal; G Laurent
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Cellular and plasma pharmacokinetics of weekly 20-mg 4'-epi-adriamycin bolus injection in patients with advanced breast carcinoma.

Authors:  P A Speth; P C Linssen; L V Beex; J B Boezeman; C Haanen
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients.

Authors:  P A Speth; P C Linssen; J B Boezeman; H M Wessels; C Haanen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Circadian rhythm and seasonal dependence in the toxicological response of mice to epirubicin.

Authors:  M C Mormont; R von Roemeling; R B Sothern; J S Berestka; T R Langevin; M Wick; W J Hrushesky
Journal:  Invest New Drugs       Date:  1988-12       Impact factor: 3.850

10.  A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat.

Authors:  G Storm; Q G van Hoesel; G de Groot; W Kop; P A Steerenberg; F C Hillen
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.